Jensa Mariam Joseph
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jensa Mariam Joseph has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Fatima Mraiche
Department of Pharmacology, Faculty of Medicine and Dentistry, College of Health Sciences University of Alberta Edmonton Alberta Canada
1 shared publication - Hend Al-Sulaiti
College of Pharmacy, Qatar University, P.O. Box 2713, Doha, Qatar
1 shared publication - Iman W. Achkar
Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar
1 shared publication - Nabeel Abdulrahman
Translational Research Institute, Academic Health System, Hamad Medical Corporation, P.O. Box 3050 Doha, Qatar
1 shared publication - Shahab Uddin
Translational Research Institute, Academic Health System, Hamad Medical Corporation
1 shared publication
Latest Publications
- Open Access
- 11 April 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-12
Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin.
- 11 April 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-12
Open AccessCisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin.